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BACKGROUND: We examined the associations between germline variants and breast cancer mortality using a large meta-analysis
of women of European ancestry.
METHODS: Meta-analyses included summary estimates based on Cox models of twelve datasets using ~10.4 million variants for
96,661 women with breast cancer and 7697 events (breast cancer-speciﬁc deaths). Oestrogen receptor (ER)-speciﬁc analyses were
based on 64,171 ER-positive (4116) and 16,172 ER-negative (2125) patients. We evaluated the probability of a signal to be a true
positive using the Bayesian false discovery probability (BFDP).
RESULTS: We did not ﬁnd any variant associated with breast cancer-speciﬁc mortality at P < 5 × 10−8. For ER-positive disease, the
most signiﬁcantly associated variant was chr7:rs4717568 (BFDP= 7%, P= 1.28 × 10−7, hazard ratio [HR]= 0.88, 95% conﬁdence
interval [CI]= 0.84–0.92); the closest gene is AUTS2. For ER-negative disease, the most signiﬁcant variant was chr7:rs67918676
(BFDP= 11%, P= 1.38 × 10−7, HR= 1.27, 95% CI= 1.16–1.39); located within a long intergenic non-coding RNA gene (AC004009.3),
close to the HOXA gene cluster.
CONCLUSIONS: We uncovered germline variants on chromosome 7 at BFDP < 15% close to genes for which there is biological
evidence related to breast cancer outcome. However, the paucity of variants associated with mortality at genome-wide signiﬁcance
underpins the challenge in providing genetic-based individualised prognostic information for breast cancer patients.
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BACKGROUND
Breast cancer is the most common cancer in the Western world
and accounts for 15% of cancer-related deaths in women, with
about 522,000 deaths worldwide in 2012.1 Survival after a
diagnosis of breast cancer varies considerably between patients
even with closely matching tumour characteristics. Models that
predict the likelihood of survival after breast cancer treatment use
tumour and treatment data, but currently do not take host factors
into account. The identiﬁcation of prognostic and predictive
biomarkers inherent in the germline of the patients rather than
the tumour could pinpoint mechanisms of tumour progression
and help with treatment stratiﬁcation to increase therapeutic
beneﬁt. Such markers include inherited genetic variation, as there
is evidence for heritability of breast cancer-speciﬁc mortality in
affected ﬁrst-degree relatives.2–5 Germline variation may affect
prognosis by affecting tumour biology, since such variants are
known to be associated with risk of speciﬁc breast tumour
subtypes, particularly those deﬁned by hormone receptor status,
and have different outcomes.6–8 Germline genotype could also
affect the efﬁcacy of adjuvant drug therapies9,10 or might
condition the host tumour environment via vascularisation,11,12
metastatic pattern,13,14 stroma–tumour interaction15,16 and
immune surveillance.17,18
The association between common germline genetic variation
and breast cancer-speciﬁc mortality has been examined in many
candidate gene studies,5,9,14,19–36 as well as in moderate-sized
genome-wide association studies (GWAS).37–41 However, it has
been difﬁcult link GWAS results to plausible candidate genes and
few have been convincingly replicated.29,42 Large studies with
long follow-up and reliable data on known prognostic factors are
required if novel alleles associated with prognosis in breast cancer
are to be identiﬁed at a level of genome-wide signiﬁcance. In the
present work, we pooled genotype data from multiple breast
cancer GWAS discovery and replication efforts43,44 with new
genotype data obtained from a large breast cancer series
genotyped using the OncoArray chip.45,46 We examined associa-
tions with risk of breast cancer-speciﬁc mortality in a total of
96,661 breast cancer patients with survival time data. We then
investigated the potential functional role of the selected variants
by predicting possible target genes.
MATERIALS AND METHODS
Breast cancer patient samples
We included data from twelve datasets (n= 96,661) in which
multiple breast cancer patient cohorts were genotyped by a
variety of arrays providing genome-wide coverage of common
variants. An overview of the datasets with speciﬁcation of the
arrays used is given in Supplementary Table 1. Data from eight of
these datasets have been used in previous analyses (n= 37,954).44
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However, the Collaborative Oncological Gene-Environment Study
(COGS) dataset from the Breast Cancer Association Consortium
(BCAC) was updated to include additional follow-up and death
events and additional genotype data, increasing the number of
events and samples to a total of n= 29,959 patients. Two new
datasets, the BCAC OncoArray and the SUCCESS A trial, comprising
58,027 samples, were added for the current analyses.
The OncoArray is a custom Illumina genotyping array designed
by the Genetic Associations and Mechanisms in Oncology (GAME-
ON) consortium. It includes 533,000 variants of which 260,660
form a GWAS backbone, with the remainder being custom
content, details of which have been described previously.45 The
SUCCESS-A Study47 is a randomised phase III study of n= 3,299
breast cancer cases. Cases from the trial were genotyped using the
Illumina Human OmniExpress array. We downloaded imputed
genotypes from dbGaP (data reference 6266).
COGS samples that were also genotyped on the OncoArray
were removed from the COGS dataset (n= 14,426). Female
patients with invasive breast cancer diagnosed at age > 18 years,
and with follow-up data available were included in the analyses.
BCAC data from freeze 8 was used, in which 873 COGS samples
with unknown breast cancer-speciﬁc mortality status were
excluded from the analyses. All stages of cancer, including
metastatic, were used in the analysis. Some individual studies
applied additional selection criteria such as young age or early
breast cancer stage (Supplementary Table 2).
Genotype and sample quality control, ancestry analysis and
imputation
The genotype and sample quality control for the datasets have
been described previously.44,45,47,48 Ancestry outliers for each
dataset were identiﬁed by multidimensional scaling or LAMP49 on
the basis of a set of unlinked variants and HapMap2 populations.
Samples of European ancestry were retained for analyses.
Ten of the datasets were imputed using the reference panel
from the 1000 Genomes Project in a two-stage procedure. The
1000 Genomes project Phase 3 (October 2014) release was used as
the reference panel for all the datasets apart from SUCCESS-A,
which used the Phase 1 release (March 2012). Imputation for
CGEMS and BPC3 was performed using the programme MACH.50
Phased genotypes were ﬁrst derived using SHAPEIT51 and
IMPUTE252 and then used to perform imputation on the phased
data. The main analyses were based on variants that were
imputed with imputation r2 > 0.3 and had minor allele frequency
(MAF) > 0.01 in at least one of the datasets leading to ~10.4 million
variants. To match the individual datasets in the meta-analysis we
used the chromosome position. Variants were kept in the analysis
as long as they were present in one of the studies. In those cases
where there was ambiguity over the naming of the insertions and
deletions, the MAF was used for further matching.
Statistical and bioinformatic methods
Time-to-event was calculated from the date of diagnosis. For
prevalent cases with study entry after diagnosis left truncation
was applied, i.e., follow-up started at the date of study entry.53
Follow-up was right censored on the date of death, on the date
last known alive if death did not occur, or at 15 years after
diagnosis, whichever came ﬁrst. We chose the 15 years cut-off
because follow-up varied between studies and after that period
follow-up data became scarce. Follow-up of the cohorts is
illustrated in Kaplan Meier curves (Supplementary Figure 1).
The hazard ratios (HR) for the association of genotypes with
breast cancer-speciﬁc mortality were estimated using Cox
proportional hazards regression54 implemented in an in-house
programme written in C++. Analysis of the CGEMS and BPC3 data
was conducted using ProbABEL.55 The estimates of the individual
studies were combined using an inverse-variance weighted meta-
analysis. Since meta-analysis results based on the Wald test have
been shown to be inﬂated for rare variants56 we recomputed the
standard errors based on the likelihood ratio test statistic (see
details in Supplementary methods), using the formula:
SE ¼ log HRð Þ=sqrt LRTð Þ
For each dataset we included as covariates a variable number of
principal components (Supplementary Table 1) from the ancestry
analysis as covariates in order to control for cryptic population
substructure. The Cox models were stratiﬁed by country for the
OncoArray dataset and by study for the COGS dataset. Statistical
tests were performed for each variant by combining the results for
all the datasets using a ﬁxed-effects meta-analysis. Inﬂation of the
test statistics (λ) was estimated by dividing the 45th percentile of
the test statistic by 0.357 (the 45th percentile for a χ2 distribution
on 1 degree of freedom). Analyses were carried out for all invasive
breast cancer and for oestrogen receptor (ER)-positive and ER-
negative disease separately.
To assess the probability of a variant being a false positive we
used a Bayesian false discovery probability (BFDP)57 test based on
the P value, a prior set to 0.0001 and an upper likely HR of 1.3.
To predict potential target genes, we used Bedtools v2.26 to
intersect notable variants with genomic annotation data relevant to
gene regulation activity in samples derived from breast tissue. We
examined features including enhancers, promoters and transcription
factor binding sites identiﬁed by the Roadmap58 and ENCODE59
Projects. Expression quantitative loci (eQTL) data from GTEx60 were
queried for evidence of potential cis-regulatory activity.
RESULTS
Genotype data from 96,661 breast cancer cases (64,171 ER-positive
and 16,172 ER-negative) with 7697 breast cancer deaths within
15 years were included in the primary analyses. For 16,318 cases we
did not have ER-status information. The average follow-up time was
6.38 years. Details of the numbers of samples and events in each
dataset are given in Supplementary Table 3. Manhattan and
quantile-quantile (Q–Q) plots for the associations between variants
and breast cancer-speciﬁc mortality of all invasive, ER-negative
and ER-positive breast cancers are shown in Fig. 1 and Fig. 2,
respectively. There was some evidence of inﬂation of the test
statistic with an inﬂation factor of 1.06 for all invasive and
ER-positive, and 1.05 for ER-negative including all variants. These
Q–Q plots showed no evidence of an association at P < 5 × 10−8; at
less stringent thresholds for signiﬁcance, there were an increasing
number of observed associations for all three analyses (Fig. 2).
We identiﬁed three variants at BFDP < 15% associated with
breast cancer-speciﬁc mortality of patients with ER-negative
disease (Table 1). These variants are part of an independent set
of 32 highly correlated variants61 on chromosome 7q21.1 that
were associated at P < 5 × 10−6 (Supplementary Table 4). The LD
matrix between these variants computed based on the 1000
European genomes,62,63 and their chromosomal positions, are
shown in Supplementary Figure 1. The strongest association was
for rs67918676: HR= 1.27; 95% CI= 1.16–1.39; P= 1.38 × 10−7;
risk allele A frequency= 0.12 and BFDP= 11%. The imputation
efﬁciency for this variant was high, with r2= 0.99 for all datasets.
The lead variant rs67918676 is located in an intron of a long
intergenic non-coding RNA gene, LOC105375207 (AC004009.3), in
close proximity to the HOXA gene cluster and the lncRNA HOTTIP.
We tested the genes within a 500 MBp window around the 32
highly correlated variants for the association of their mRNA
expression in breast tumours with recurrence-free survival using
KMplotter (kmplot.com/analysis). Four of the ten closest genes
with probes available showed moderate association with breast
cancer survival at P < 0.005 (HOXA9, HOTTIP, EVX1 and TAX1BP1),
with these associations mainly observed for ER-negative breast
cancer (Supplementary Table 5A). Yet, intersecting the germline
variants with several sources of genomic annotation information
Genome-wide association study of germline variants and breast. . .
M Escala-Garcia et al.
648
1
2
3
4
5
6
7
8
9
0
()
;,:
(e.g., chromosome conformation, enhancer–promoter correlations
or gene expression) we could not ﬁnd strong in silico evidence of
gene regulation by the region containing the associated variants.
We also identiﬁed four variants at a BFDP < 15% associated with
breast cancer-speciﬁc mortality of patients with ER-positive
disease (Table 1). These variants were part of an independent
set of 45 highly correlated variants on chromosome 7q11.22 that
were associated at P < 5 × 10−6 (Supplementary Table 6). The LD
matrix between these variants computed based on the 1000
European genomes,62,63 and their chromosomal positions, are
shown in Supplementary Figure 3. The strongest association was
for rs4717568: HR= 0.88; 95% CI:0.84–0.92; P= 1.28 × 10−7; risk
allele A frequency= 0.62 and BFDP= 7%. The imputation
efﬁciency for this variant was high, with an average r2= 0.96
for all datasets. Two coding genes, AUTS2 and GALNT17, were
located within a 500 MBp window around the 45 highly correlated
variants, but the expression of neither of the two was associated
with breast cancer survival in KMplotter analyses of TCGA data
(Supplementary Table 5B).
The association of rs67918676 with ER-negative breast cancer
was observed in eight of nine studies with no signiﬁcant
heterogeneity present at P < 0.01 (Fig. 3 and Supplementary
Figure 4a). For ER-positive disease, the association of rs4717568
was detected in all seven studies with no heterogeneity present at
P < 0.01 (Fig. 4 and Supplementary Figure 4b).
Apart from the 7q variants, only one isolated rare variant
reached BFDP values below 15% for all tumours (Table 1). The
variant, rs370332736: HR= 1.17; 95% CI: 1.10–1.24; P= 2.48 ×
10−7; risk allele A frequency= 0.09 and BFDP= 13%, is located
on chromosome 6 and has an average imputation efﬁciency of
r2= 0.96 for all datasets. In addition, there were several variants
found at P < 10−6 for all three analyses (Supplementary Table 4,
Supplementary Table 6 and Supplementary Table 7).
DISCUSSION
In this large survival analysis, we report a genome-wide study for
identifying genetic markers associated with breast cancer-speciﬁc
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Fig. 1 Association plot for the meta-analysis of the twelve datasets for breast cancer-speciﬁc mortality analyses (censored at 15 years) for a all
breast tumours (censored at 15 years), b ER-negative tumours and c ER-positive tumours. The y-axis shows the −log10 P values of each variant
analysed, and the x-axis shows their chromosome position. The red horizontal line represents P= 5 × 10−8
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Fig. 2 Q–Q plots for the meta-analysis of the twelve datasets for breast cancer-speciﬁc mortality analyses (censored at 15 years) for a all breast
cancer tumours (censored at 15 years), b ER-negative tumours and c ER-positive tumours. The y-axis represents the observed −log10 P value,
and the x-axis represents the expected −log10 P value. The red line represents the expected distribution under the null hypothesis of no
association. Analyses were not corrected for LD-structure
Table 1. Results of the variants with BFDP < 15% in the meta-analysis of the 12 studies of breast cancer-speciﬁc mortality
Subgroup Variant Chr Position Alt Ref Eaf_Ref HR LCL UCL P value BFDP
ER-negative rs67918676:27445956:A:AT 7 27445956 AT A 0.12 1.27 1.16 1.39 1.38 × 10−7 0.11
ER-negative rs192185001:27448012:A:AT 7 27448012 AT A 0.12 1.27 1.16 1.39 1.66 × 10−7 0.13
ER-negative rs145963877:27473909:CAG:C 7 27473909 C CAG 0.11 1.28 1.17 1.41 1.91 × 10−7 0.15
ER-positive rs4717568:70400700:T:C 7 70400700 C T 0.62 0.88 0.8 0.92 1.28 × 10−7 0.07
ER-positive rs1917618:70396442:T:A 7 70396442 A T 0.62 0.88 0.84 0.93 1.46 × 10−7 0.08
ER-positive rs1546774:70398441:T:G 7 70398441 G T 0.62 0.88 0.84 0.93 1.66 × 10−7 0.09
ER-positive rs1546773:70398437:T:C 7 70398437 C T 0.62 0.88 0.84 0.93 1.81 × 10−7 0.10
All rs370332736:50395136:AACTT:A 6 50395136 A AACTT 0.09 1.16 1.10 1.24 2.48 × 10−7 0.13
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mortality, involving 96,661 patients from a combined meta-
analysis. We found one noteworthy region with 32 highly
correlated variants on chromosome 7q21.1 for ER-negative. The
lead variant rs67918676 (P= 1.38 × 10−7 and BFDP of 11% under
reasonable assumptions for the prior probability of association) is
located in a long intergenic non-coding RNA gene (AC004009.3).
While this represents an uncharacterised transcript mainly
expressed in testis and prostate, it is located about 200 kb away
from a cluster of HOXA homeobox genes that has been implicated
in breast cancer aetiology and prognosis.64,65 This region also
contains HOTTIP, a lncRNA with prognostic value on clinical
outcome in breast cancer.66 The ﬂanking region on the opposite
side contains TAX1BP1, a gene that may be involved in
chemosensitivity.67 Interestingly, database mining using KMplotter
revealed evidence for an association of the expression of these
nearby genes with survival from ER-negative breast cancer. On the
other hand, the enhancer activity at this noteworthy locus was
predicted to be low based on the intersection with biofeatures
characteristic of regulatory activity as no known eQTLs appear to
exist in this region, suggesting that gene regulatory effects of
the identiﬁed variants are limited in breast tissue or may be
activated under certain untested conditions. For ER-positive
tumours, we found another noteworthy region with 45 highly
correlated variants at P < 5 × 10E−6 on chromosome 7q11.22. The
lead variant rs4717568 (P= 1.28 × 10−7 and BFDP of 7%) is located
between the AUTS2 and the GALNT17 genes. GALNT17 encodes an
N-acetylgalactosaminyltransferase that may play a role in mem-
brane trafﬁcking.68 AUTS2 has been implicated in neurodevelop-
ment,69 but AUTS2 overexpression in cancer has also been linked
with resistance to chemotherapy and epithelial-to-mesenchymal
transition.70 It has been postulated that overexpression of AUTS2 is
speciﬁc for metastases,70 which may be consistent with the
inconspicuous gene expression results in the TCGA database.
It is important to note the differences between the present and
the previous GWAS study we had undertaken,44 the latter done in a
much smaller dataset (3632 events versus 7697 events in
the current study) that did not include the OncoArray study.
The OncoArray study is the largest dataset used in the present
meta-analysis and also the study with the highest imputation
quality. The two previously reported variants (rs148760487 for all
breast cancer tumours and rs2059614 for ER-negative tumours)
were not associated with breast cancer-speciﬁc mortality in
the current analyses (P= 1.59 × 10−3 and P= 5.41 × 10−4, respec-
tively). The most likely explanation for this is that the original
results were false-positive ﬁndings, despite the original
association being nominally “genome-wide signiﬁcant”. The BDFPs
for the original reported associations were 54% and 16%,
respectively. For the lead variants identiﬁed in the present analysis,
we tested for differences in the imputation quality between the
current and previous analysis. All variants had high imputation
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Fig. 3 Forest plot showing the association between the ER-negative variant rs67918676 and breast cancer-speciﬁc mortality in ER-negative
tumours for the datasets used in the meta-analysis. The size of the square reﬂects the size of the study (see also Supplementary Table 3)
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quality (~0.99) in the previous study, suggesting that the longer and
more complete follow-up together with a higher number of events
allowed more robust identiﬁcation of breast cancer mortality
associations. However, there are some weaknesses of the current
meta-analysis such as heterogeneity between patient treatment
over time and between countries and between datasets with
different study designs that should be considered. These limita-
tions, intrinsic to large survival meta-analyses, increase the noise
and reduce the power to detect true associations.
In conclusion, we found two novel candidate regions
at chromosome 7 for breast cancer survival, credible at a BFDP
< 15% and associated with either ER-negative or ER-positive breast
cancer-speciﬁc mortality. Concerning additional variants, we
might still be underpowered to obtain a more comprehensive
picture of genomic markers for breast cancer outcome. Overall,
the role of germline variants in breast cancer mortality is still
unclear36,37,71 and additional analyses with larger sample sizes and
more complete follow-up including treatments are needed. In
addition, alternative methods that integrate multiple data sources
such as gene expression, protein–protein interactions or pathway
analyses may be used to aggregate the effect of multiple variants
with small effects.72 Such approaches could increase the power of
the analyses while better explaining the underlying biological
mechanisms associated with breast cancer mortality.
ACKNOWLEDGEMENTS
BCAC: We thank all the individuals who took part in these studies and all the
researchers, clinicians, technicians and administrative staff who have enabled this
work to be carried out. We acknowledge all contributors to the COGS and OncoArray
study design, chip design, genotyping and genotype analyses. ABCFS thank Maggie
Angelakos, Judi Maskiell and Gillian Dite. ABCS thanks Frans Hogervorst, Sten
Cornelissen and Annegien Broeks. ABCTB Investigators: Christine Clarke, Rosemary
Balleine, Robert Baxter, Stephen Braye, Jane Carpenter, Jane Dahlstrom, John Forbes,
Soon Lee, Debbie Marsh, Adrienne Morey, Nirmala Pathmanathan, Rodney Scott,
Allan Spigelman, Nicholas Wilcken and Desmond Yip. Samples are made available to
researchers on a non-exclusive basis. BBCS thanks Eileen Williams, Elaine Ryder-Mills
and Kara Sargus. The BCINIS study would not have been possible without the
contributions of Dr. K. Landsman, Dr. N. Gronich, Dr. A. Flugelman, Dr. W. Saliba, Dr. E.
Liani, Dr. I. Cohen, Dr. S. Kalet, Dr. V. Friedman and Dr. O. Barnet of the NICCC in Haifa,
and all the contributing family medicine, surgery, pathology and oncology teams in
all medical institutes in Northern Israel. BIGGS thanks Niall McInerney, Gabrielle
Colleran, Andrew Rowan and Angela Jones. The BREOGAN study would not have
been possible without the contributions of the following: Manuela Gago-Dominguez,
Jose Esteban Castelao, Angel Carracedo, Victor Muñoz Garzón, Alejandro Novo
Domínguez, Maria Elena Martinez, Sara Miranda Ponte, Carmen Redondo Marey,
Maite Peña Fernández, Manuel Enguix Castelo, Maria Torres, Manuel Calaza
(BREOGAN), José Antúnez, Máximo Fraga and the staff of the Department of
Pathology and Biobank of the University Hospital Complex of Santiago-CHUS,
Instituto de Investigación Sanitaria de Santiago, IDIS, Xerencia de Xestion Integrada
de Santiago—SERGAS; Joaquín González-Carreró and the staff of the Department of
Pathology and Biobank of University Hospital Complex of Vigo, Instituto de
Investigacion Biomedica Galicia Sur, SERGAS, Vigo, Spain. BSUCH thanks Peter
Bugert, Medical Faculty Mannheim. CCGP thanks Styliani Apostolaki, Anna Margiolaki,
Georgios Nintos, Maria Perraki, Georgia Saloustrou, Georgia Sevastaki and
Konstantinos Pompodakis. CGPS thanks staff and participants of the Copenhagen
General Population Study. For the excellent technical assistance: Dorthe Uldall
Andersen, Maria Birna Arnadottir, Anne Bank and Dorthe Kjeldgård Hansen. The
Danish Cancer Biobank is acknowledged for providing infrastructure for the
collection of blood samples for the cases. CNIO-BCS thanks Guillermo Pita, Charo
Alonso, Nuria Álvarez, Pilar Zamora, Primitiva Menendez and the Human Genotyping-
CEGEN Unit (CNIO). Investigators from the CPS-II cohort thank the participants and
Study Management Group for their invaluable contributions to this research. They
also acknowledge the contribution to this study from central cancer registries
supported through the Centers for Disease Control and Prevention National
Programme of Cancer Registries, as well as cancer registries supported by the
National Cancer Institute Surveillance Epidemiology and End Results programme. The
CTS Steering Committee includes Leslie Bernstein, Susan Neuhausen, James Lacey,
Sophia Wang, Huiyan Ma, and Jessica Clague DeHart at the Beckman Research
Institute of City of Hope, Dennis Deapen, Rich Pinder, and Eunjung Lee at the
University of Southern California, Pam Horn-Ross, Peggy Reynolds, Christina Clarke
Dur and David Nelson at the Cancer Prevention Institute of California, Hoda Anton-
Culver, Argyrios Ziogas, and Hannah Park at the University of California Irvine and
Fred Schumacher at Case Western University. DIETCOMPLYF thanks the patients,
nurses and clinical staff involved in the study. The DietCompLyf study was funded by
the charity Against Breast Cancer (Registered Charity Number 1121258) and the
NCRN. We thank the participants and the investigators of EPIC (European Prospective
Investigation into Cancer and Nutrition). ESTHER thanks Hartwig Ziegler, Sonja Wolf,
Volker Hermann, Christa Stegmaier and Katja Butterbach. FHRISK thanks NIHR for
funding. GC-HBOC thanks Stefanie Engert, Heide Hellebrand, Sandra Kröber and LIFE
—Leipzig Research Centre for Civilisation Diseases (Markus Loefﬂer, Joachim Thiery,
Matthias Nüchter and Ronny Baber). The GENICA Network: Dr. Margarete Fischer-
Bosch-Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen,
Germany [H.B. and W.Y.L.], German Cancer Consortium (DKTK) and German Cancer
Research Center (DKFZ) [H.B.], Department of Internal Medicine, Evangelische
Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany [Y.D.K., Christian
Baisch], Institute of Pathology, University of Bonn, Germany [Hans-Peter Fischer],
Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ),
Heidelberg, Germany [UH], Institute for Prevention and Occupational Medicine of the
German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA),
Bochum, Germany [Thomas Brüning, Beate Pesch, Sylvia Rabstein, Anne Lotz]; and
Institute of Occupational Medicine and Maritime Medicine, University Medical Centre
Hamburg-Eppendorf, Germany [Volker Harth]. HABCS thanks Michael Bremer. HEBCS
thanks, Rainer Fagerholm, Kirsimari Aaltonen, Karl von Smitten, Irja Erkkilä. HUBCS
thanks Shamil Gantsev. KARMA and SASBAC thank the Swedish Medical Research
Counsel. KBCP thanks Eija Myöhänen, Helena Kemiläinen. kConFab/AOCS wish to
thank Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and staff,
the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study
(which has received funding from the NHMRC, the National Breast Cancer
Foundation, Cancer Australia, and the National Institute of Health (USA)) for their
contributions to this resource, and the many families who contribute to kConFab.
LMBC thanks Gilian Peuteman, Thomas Van Brussel, EvyVanderheyden and Kathleen
Corthouts. MARIE thanks Petra Seibold, Judith Heinz, Nadia Obi, Alina Vrieling, Sabine
Behrens, Ursula Eilber, Muhabbet Celik, Til Olchers and Stefan Nickels. MBCSG: Paolo
Peterlongo, Bernard Peissel, Roberto Villa, Cristina Zanzottera, Irene Feroce, and the
personnel of the Cogentech Cancer Genetic Test Laboratory. We thank the
coordinators, the research staff and especially the MMHS participants for their
continued collaboration on research studies in breast cancer. The following are NBCS
Collaborators: Kristine K. Sahlberg (Ph.D.), Lars Ottestad (M.D.), Rolf Kåresen (Prof. Em.)
Dr. Ellen Schlichting (M.D.), Marit Muri Holmen (M.D.), Toril Sauer (M.D.), Vilde
Haakensen (M.D.), Olav Engebråten (M.D.), Bjørn Naume (M.D.), Alexander Fosså (M.
D.), Cecile E. Kiserud (M.D.), Kristin V. Reinertsen (M.D.), Åslaug Helland (M.D.), Margit
Riis (M.D.), Jürgen Geisler (M.D.) and OSBREAC. NHS/NHS2 would like to thank the
participants and staff of the NHS and NHS2 for their valuable contributions as well
as the following state cancer registries for their help: A.L., A.Z., A.R., C.A., C.O., C.T., D.E.,
F.L., G.A., I.D., I.L., I.N., I.A., K.Y., L.A., M.E., M.D., M.A., M.I., N.E., N.H., N.J., N.Y., N.C., N.D.,
O.H., O.K., O.R., P.A., R.I., S.C., T.N., T.X., V.A., W.A., W.Y. OBCS thanks Arja Jukkola-
Vuorinen, Mervi Grip, Saila Kauppila, Meeri Otsukka, Leena Keskitalo and Kari
Mononen for their contributions to this study. OFBCR thanks Teresa Selander and
Nayana Weerasooriya. ORIGO thanks E. Krol-Warmerdam, and J. Blom for patient
accrual, administering questionnaires and managing clinical information. PBCS
thanks Louise Brinton, Mark Sherman, Neonila Szeszenia-Dabrowska, Beata
Peplonska, Witold Zatonski, Pei Chao and Michael Stagner. The ethical approval for
the POSH study is MREC/00/6/69, UKCRN ID: 1137. We thank staff in the Experimental
Cancer Medicine Centre (ECMC) supported Faculty of Medicine Tissue Bank and the
Faculty of Medicine DNA Banking resource. PREFACE thanks Sonja Oeser and Silke
Landrith. PROCAS thanks NIHR for funding. RBCS thanks Petra Bos, Jannet Blom, Ellen
Crepin, Elisabeth Huijskens, Anja Kromwijk-Nieuwlaat, Annette Heemskerk and the
Erasmus MC Family Cancer Clinic. SBCS thanks Sue Higham, Helen Cramp, Dan
Connley, Ian Brock, Sabapathy Balasubramanian and Malcolm W.R. Reed. We thank
the SEARCH and EPIC teams. SKKDKFZS thanks all study participants, clinicians, family
doctors, researchers and technicians for their contributions and commitment to this
study. We thank the SUCCESS Study teams in Munich, Duessldorf, Erlangen and Ulm.
We thank the SUCCESS Study teams in Munich, Duessldorf, Erlangen and Ulm. SZBCS
thanks Ewa Putresza. UCIBCS thanks Irene Masunaka. UKBGS thanks Breast Cancer
Now and the Institute of Cancer Research for support and funding of the
Breakthrough Generations Study, and the study participants, study staff, and the
doctors, nurses and other health care providers and health information sources who
have contributed to the study. We acknowledge NHS funding to the Royal Marsden/
ICR NIHR Biomedical Research Centre. The authors thank the WHI investigators and
staff for their dedication and the study participants for making the programme
possible. BCAC is funded by Cancer Research UK [C1287/A16563 and C1287/A10118],
the European Union’s Horizon 2020 Research and Innovation Programme (Grant
numbers 634935 and 633784 for BRIDGES and B-CAST, respectively), and by the
European Community's Seventh Framework Programme under grant agreement
number 223175 (Grant number HEALTH-F2-2009-223175) (COGS). The EU Horizon
2020 Research and Innovation Programme funding source had no role in study
Genome-wide association study of germline variants and breast. . .
M Escala-Garcia et al.
651
design, data collection, data analysis, data interpretation or writing of the report.
Genotyping of the OncoArray was funded by the NIH Grant U19 CA148065, and
Cancer UK Grant C1287/A16563 and the PERSPECTIVE project supported by the
Government of Canada through Genome Canada and the Canadian Institutes of
Health Research (Grant GPH-129344) and, the Ministère de l’Économie, Science et
Innovation du Québec through Genome Québec and the PSRSIIRI-701 grant, and the
Quebec Breast Cancer Foundation. Funding for the iCOGS infrastructure came from:
the European Community’s Seventh Framework Programme under grant agreement
no. 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118,
C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007,
C5047/A10692 and C8197/A16565), the National Institutes of Health (CA128978)
and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19
CA148112—the GAME-ON initiative), the Department of Defence (W81XWH-10-1-
0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial
Risks of Breast Cancer, and Komen Foundation for the Cure, the Breast Cancer
Research Foundation, and the Ovarian Cancer Research Fund. The DRIVE Consortium
was funded by U19 CA148065. ABCFS was supported by grant UM1 CA164920 from
the National Cancer Institute (USA). The content of this manuscript does not
necessarily reﬂect the views or policies of the National Cancer Institute or any of the
collaborating centres in the in the Breast Cancer Family Registry (BCFR), nor does
mention of trade names, commercial products, or organisations imply endorsement
by the USA Government or the BCFR. The ABCFS was also supported by the National
Health and Medical Research Council of Australia, the New South Wales Cancer
Council, the Victorian Health Promotion Foundation (Australia) and the Victorian
Breast Cancer Research Consortium. J.L.H. is a National Health and Medical Research
Council (NHMRC) Senior Principal Research Fellow. M.C.S. is a NHMRC Senior Research
Fellow. The ABCS study was supported by the Dutch Cancer Society [Grants NKI 2007-
3839; 2009-4363 and2015-7632]. The ABCTB is generously supported by the National
Health and Medical Research Council of Australia, The Cancer Institute NSW and the
National Breast Cancer Foundation. The work of the BBCC was partly funded by
ELAN-Fond of the University Hospital of Erlangen. The BBCS is funded by Cancer
Research UK and Breast Cancer Now and acknowledges NHS funding to the NIHR
Biomedical Research Centre, and the National Cancer Research Network (NCRN). For
the BCFR-NY, BCFR-PA, BCFR-UT this work was supported by grant UM1 CA164920
from the National Cancer Institute. For BIGGS, ES is supported by NIHR
Comprehensive Biomedical Research Centre, Guy’s & St. Thomas’ NHS Foundation
Trust in partnership with King’s College London, United Kingdom. IT is supported by
the Oxford Biomedical Research Centre. The BREOGAN is funded by Acción
Estratégica de Salud del Instituto de Salud Carlos III FIS PI12/02125/Coﬁnanciado
FEDER; Acción Estratégica de Salud del Instituto de Salud Carlos III FIS Intrasalud
(PI13/01136); Programa Grupos Emergentes, Cancer Genetics Unit, Instituto de
Investigacion Biomedica Galicia Sur. Xerencia de Xestion Integrada de Vigo-SERGAS,
Instituto de Salud Carlos III, Spain; Grant 10CSA012E, Consellería de Industria
Programa Sectorial de Investigación Aplicada, PEME I + D e I + D Suma del Plan
Gallego de Investigación, Desarrollo e Innovación Tecnológica de la Consellería de
Industria de la Xunta de Galicia, Spain; Grant EC11-192. Fomento de la Investigación
Clínica Independiente, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain;
and Grant FEDER-Innterconecta. Ministerio de Economia y Competitividad, Xunta de
Galicia, Spain. The BSUCH study was supported by the Dietmar-Hopp Foundation, the
Helmholtz Society and the German Cancer Research Center (DKFZ). CCGP is
supported by funding from the University of Crete. The CECILE study was supported
by Fondation de France, Institut National du Cancer (INCa), Ligue Nationale contre le
Cancer, Agence Nationale de Sécurité Sanitaire, de l’Alimentation, de l’Environne-
ment et du Travail (ANSES), Agence Nationale de la Recherche (ANR). The CGPS was
supported by the Chief Physician Johan Boserup and Lise Boserup Fund, the Danish
Medical Research Council, and Herlev and Gentofte Hospital. The CNIO-BCS was
supported by the Instituto de Salud Carlos III, the Red Temática de Investigación
Cooperativa en Cáncer and grants from the Asociación Española Contra el Cáncer
and the Fondo de Investigación Sanitario (PI11/00923 and PI12/00070). The American
Cancer Society funds the creation, maintenance, and updating of the CPS-II cohort.
The CTS was initially supported by the California Breast Cancer Act of 1993 and the
California Breast Cancer Research Fund (Contract 97-10500) and is currently funded
through the National Institutes of Health (R01 CA77398, UM1 CA164917 and U01
CA199277). Collection of cancer incidence data was supported by the California
Department of Public Health as part of the statewide cancer reporting programme
mandated by California Health and Safety Code Section 103885. The University of
Westminster curates the DietCompLyf database funded by Against Breast Cancer
Registered Charity No. 1121258 and the NCRN. The coordination of EPIC is ﬁnancially
supported by the European Commission (DG-SANCO) and the International Agency
for Research on Cancer. The national cohorts are supported by: Ligue Contre le
Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut
National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer
Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and
Research (BMBF) (Germany); the Hellenic Health Foundation, the Stavros Niarchos
Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and
National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports
(VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention
Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund
(WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS), PI13/
00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía,
Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain);
Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-
Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-
Oxford) (United Kingdom). The ESTHER study was supported by a grant from the
Baden Württemberg Ministry of Science, Research and Arts. Additional cases were
recruited in the context of the VERDI study, which was supported by a grant from the
German Cancer Aid (Deutsche Krebshilfe). FHRISK is funded from NIHR grant PGfAR
0707-10031. The GC-HBOC is supported by the German Cancer Aid (Grant no. 110837,
coordinator: Rita K. Schmutzler, Cologne). This work was also funded by the European
Regional Development Fund and Free State of Saxony, Germany (LIFE—Leipzig
Research Centre for Civilisation Diseases, project numbers 713-241202, 713-241202,
14505/2470 and 14575/2470). The GENICA was funded by the Federal Ministry of
Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8,
01KW9977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches
Krebsforschungszentrum (DKFZ), Heidelberg, the Institute for Prevention and
Occupational Medicine of the German Social Accident Insurance, Institute of the
Ruhr University Bochum (IPA), Bochum, as well as the Department of Internal
Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn,
Germany. The GESBC was supported by the Deutsche Krebshilfe e. V. [70492] and
the German Cancer Research Centre (DKFZ). The HABCS study was supported by the
Claudia von Schilling Foundation for Breast Cancer Research, by the Lower Saxonian
Cancer Society, and by the Rudolf Bartling Foundation. The HEBCS was ﬁnancially
supported by the Helsinki University Central Hospital Research Fund, Academy of
Finland (266528), the Finnish Cancer Society, and the Sigrid Juselius Foundation. The
HUBCS was supported by a grant from the German Federal Ministry of Research and
Education (RUS08/017), and by the Russian Foundation for Basic Research and the
Federal Agency for Scientiﬁc Organisations for support the Bioresource collections
and RFBR grants 14-04-97088, 17-29-06014 and 17-44-020498. Financial support for
KARBAC was provided through the regional agreement on medical training and
clinical research (ALF) between Stockholm County Council and Karolinska Institutet,
the Swedish Cancer Society, The Gustav V. Jubilee foundation and Bert von Kantzows
foundation. The KARMA study was supported by Märit and Hans Rausings Initiative
Against Breast Cancer. The KBCP was ﬁnancially supported by the special
Government Funding (EVO) of Kuopio University Hospital grants, Cancer Fund of
North Savo, the Finnish Cancer Organisations, and by the strategic funding of the
University of Eastern Finland. kConFab is supported by a grant from the National
Breast Cancer Foundation, and previously by the National Health and Medical
Research Council (NHMRC), the Queensland Cancer Fund, the Cancer Councils of New
South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of
Western Australia. LMBC is supported by the ‘Stichting tegen Kanker’. The MARIE
study was supported by the Deutsche Krebshilfe e.V. [70-2892-BR I, 106332, 108253,
108419, 110826 and110828], the Hamburg Cancer Society, the German Cancer
Research Centre (DKFZ) and the Federal Ministry of Education and Research (BMBF)
Germany [01KH0402]. MBCSG is supported by grants from the Italian Association for
Cancer Research (AIRC) and by funds from the Italian citizens who allocated the 5/
1000 share of their tax payment in support of the Fondazione IRCCS Istituto
Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects “5 ×
1000”). The MCBCS was supported by the NIH grants CA192393, CA116167 and
CA176785 an NIH Specialised Programme of Research Excellence (SPORE) in Breast
Cancer [CA116201], and the Breast Cancer Research Foundation and a generous gift
from the David F. and Margaret T. Grohne Family Foundation. MCCS cohort
recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was
further supported by Australian NHMRC grants 209057 and 396414, and by
infrastructure provided by Cancer Council Victoria. Cases and their vital status were
ascertained through the Victorian Cancer Registry (VCR) and the Australian Institute
of Health and Welfare (AIHW), including the National Death Index and the Australian
Cancer Database. The MEC was supported by NIH grants CA63464, CA54281,
CA098758, CA132839 and CA164973. The MISS study is supported by funding from
ERC-2011-294576 Advanced grant, Swedish Cancer Society, Swedish Research
Council, Local hospital funds, Berta Kamprad Foundation, Gunnar Nilsson. The
MMHS study was supported by NIH grants CA97396, CA128931, CA116201, CA140286
and CA177150. The work of MTLGEBCS was supported by the Quebec Breast Cancer
Foundation, the Canadian Institutes of Health Research for the “CIHR Team in Familial
Risks of Breast Cancer” programme—Grant # CRN-87521 and the Ministry of
Economic Development, Innovation and Export Trade—grant # PSR-SIIRI-701. The
NBCS has received funding from the K.G. Jebsen Centre for Breast Cancer Research;
the Research Council of Norway grant 193387/V50 (to A.-L. Børresen-Dale and V.N.
Kristensen) and grant 193387/H10 (to A.-L. Børresen-Dale and V.N. Kristensen), South
Eastern Norway Health Authority (Grant 39346 to A.-L. Børresen-Dale) and the
Norwegian Cancer Society (to A.-L. Børresen-Dale and V.N. Kristensen). The NC-BCFR
Genome-wide association study of germline variants and breast. . .
M Escala-Garcia et al.
652
and OFBCR were supported by grant UM1 CA164920 from the National Cancer
Institute (USA). The NCBCS was funded by Komen Foundation, the National Cancer
Institute (P50 CA058223, U54 CA156733 and U01 CA179715), and the North Carolina
University Cancer Research Fund. The NHS was supported by NIH grants P01
CA87969, UM1 CA186107 and U19 CA148065. The NHS2 was supported by NIH
grants UM1 CA176726 and U19 CA148065. The OBCS was supported by research
grants from the Finnish Cancer Foundation, the Academy of Finland (Grant numbers
250083 and 122715, and Centre of Excellence grant number 251314), the Finnish
Cancer Foundation, the Sigrid Juselius Foundation, the University of Oulu, the
University of Oulu Support Foundation and the special Governmental EVO funds for
Oulu University Hospital-based research activities. The ORIGO study was supported by
the Dutch Cancer Society (RUL 1997-1505) and the Biobanking and Biomolecular
Resources Research Infrastructure (BBMRI-NL CP16). The PBCS was funded by Intramural
Research Funds of the National Cancer Institute, Department of Health and Human
Services, USA. Genotyping for PLCO was supported by the Intramural Research
Programme of the National Institutes of Health, NCI, Division of Cancer Epidemiology
and Genetics. The PLCO is supported by the Intramural Research Programme of the
Division of Cancer Epidemiology and Genetics and supported by contracts from the
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health.
The POSH study is funded by Cancer Research UK (Grants C1275/A11699, C1275/
C22524, C1275/A19187 and C1275/A15956, and Breast Cancer Campaign grant
numbers 2010PR62 and 2013PR044. PROCAS is funded from NIHR grant PGfAR 0707-
10031. The RBCS was funded by the Dutch Cancer Society (DDHK 2004-3124 and DDHK
2009-4318). The SASBAC study was supported by funding from the Agency for Science,
Technology and Research of Singapore (A*STAR), the US National Institute of Health
(NIH) and the Susan G. Komen Breast Cancer Foundation. The SBCS was supported by
Shefﬁeld Experimental Cancer Medicine Centre and Breast Cancer Now Tissue Bank.
SEARCH is funded by Cancer Research UK [C490/A10124 and C490/A16561] and
supported by the UK National Institute for Health Research Biomedical Research Centre
at the University of Cambridge. The University of Cambridge has received salary support
for PDPP from the NHS in the East of England through the Clinical Academic Reserve.
SKKDKFZS is supported by the DKFZ. The SMC is funded by the Swedish Cancer
Foundation. The SZBCS was supported by Grant PBZ_KBN_122/P05/2004. The UCIBCS
component of this research was supported by the NIH [CA58860, CA92044] and the Lon
V Smith Foundation [LVS39420]. The UKBGS is funded by Breast Cancer Now and the
Institute of Cancer Research (ICR), London. ICR acknowledges NHS funding to the NIHR
Biomedical Research Centre. The USRT Study was funded by Intramural Research Funds
of the National Cancer Institute, Department of Health and Human Services, USA. The
WHI programme is funded by the National Heart, Lung, and Blood Institute,
the US National Institutes of Health and the US Department of Health and
Human Services (HHSN268201100046C, HHSN268201100001C, HHSN268201100002C,
HHSN268201100003C, HHSN268201100004C and HHSN271201100004C). This work was
also funded by NCI U19 CA148065-01.
AUTHOR CONTRIBUTIONS
M.K.S. and P.D.P.F. conceived the study. Q.G., M.E.G., S.K., C.J.T. and T.D. performed the
data analyses. M.K.S., P.D.P.F., Q.G., M.E.G., T.D. and D.M.E. were involved in the
interpretation of the data. J.D., D.F.E., P.D.P.F., S.C. and J.B. provided statistical and
computational support for the data analyses. R.K., Q.W., M.K.B. and J.D. provided
database support. M.E.G., Q.G., T.D., M.K.S. and P.D.P.F. wrote the ﬁrst draft of the
manuscript. All authors contributed data from their own studies, helped revise the
manuscript and approved the ﬁnal version.
ADDITIONAL INFORMATION
Supplementary information is available for this paper at https://doi.org/10.1038/
s41416-019-0393-x.
Competing interests: The authors declare no competing interests.
Data availability: All estimates reported in the paper are available through the BCAC
website: http://bcac.ccge.medschl.cam.ac.uk.
Ethics approval and consent to participate: The study was performed in
accordance with the Declaration of Helsinki. All individual studies, from which data
were used, were approved by the appropriate medical ethical committees and/or
institutional review boards. All study participants provided informed consent.
Consent for publication: All authors consented to this publication.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional afﬁliations.
REFERENCES
1. IARC. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
2. Hartman, M., Lindström, L., Dickman, P. W., Adami, H.-O., Hall, P. & Czene, K. Is
breast cancer prognosis inherited? Breast Cancer Res. 9, R39 (2007).
3. Lindström, L. S., Hall, P., Hartman, M., Wiklund, F., Grönberg, H. & Czene, K. Familial
concordance in cancer survival: a Swedish population-based study. Lancet Oncol.
8, 1001–6 (2007).
4. Udler, M. & Pharoah, P. D. Germline genetic variation and breast cancer survival:
prognostic and therapeutic implications. Future Oncol. 3, 491–495 (2007).
5. Verkooijen, H. M., Hartman, M., Usel, M., Benhamou, S., Neyroud-Caspar, I. &
Czene, K. et al. Breast cancer prognosis is inherited independently of patient,
tumor and treatment characteristics. Int J. Cancer 130, 2103–2110 (2012).
6. Broeks, A., Schmidt, M. K., Sherman, M. E., Couch, F. J., Hopper, J. L. & Dite, G. S.
et al. Low penetrance breast cancer susceptibility loci are associated with speciﬁc
breast tumor subtypes: ﬁndings from the Breast Cancer Association Consortium.
Hum. Mol. Genet. 20, 3289–303 (2011).
7. Yang, X. R., Chang-Claude, J., Goode, E. L., Couch, F. J., Nevanlinna, H. & Milne, R. L.
et al. Associations of breast cancer risk factors with tumor subtypes: a pooled
analysis from the Breast Cancer Association Consortium studies. J. Natl Cancer
Inst. 103, 250–263 (2011).
8. Blows, F. M., Driver, K. E., Schmidt, M. K., Broeks, A., van Leeuwen, F. E. & Wes-
seling, J. et al. Subtyping of breast cancer by immunohistochemistry to investi-
gate a relationship between subtype and short and long term survival: a
collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 7,
e1000279 (2010).
9. Fagerholm, R., Hofstetter, B., Tommiska, J., Aaltonen, K., Vrtel, R. & Syrjäkoski, K.
et al. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong
prognostic and predictive factor in breast cancer. Nat. Genet. 40, 844–53 (2008).
10. Hoskins, J. M., Carey, L. A. & McLeod, H. L. CYP2D6 and tamoxifen: DNA matters in
breast cancer. Nat. Rev. Cancer 9, 576–586 (2009).
11. Koutras, A., Kotoula, V. & Fountzilas, G. Prognostic and predictive role of vascular
endothelial growth factor polymorphisms in breast cancer. Pharmacogenomics
16, 79–94 (2015).
12. Hein, A., Lambrechts, D., von Minckwitz, G., Häberle, L., Eidtmann, H. & Tesch, H.
et al. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer
patients receiving bevacizumab: results from the randomized phase III Gepar-
Quinto study. Int J. Cancer 137, 2981–8 (2015).
13. Hsieh, S. M., Lintell, Na & Hunter, K. W. Germline polymorphisms are potential
metastasis risk and prognosis markers in breast cancer. Breast Dis. 26, 157–62
(2007).
14. Crawford, N. P. S., Ziogas, A., Peel, D. J., Hess, J., Anton-Culver, H. & Hunter, K. W.
Germline polymorphisms in SIPA1 are associated with metastasis and other
indicators of poor prognosis in breast cancer. Breast Cancer Res 8, R16 (2006).
15. Paulsson, J. & Micke, P. Prognostic relevance of cancer-associated ﬁbroblasts in
human cancer. Semin Cancer Biol. 25, 61–8 (2014).
16. Winslow, S., Leandersson, K., Edsjö, A. & Larsson, C. Prognostic stromal gene
signatures in breast cancer. Breast Cancer Res 17, 23 (2015).
17. Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G. & Van Eenoo, F. et al. Prognostic
and predictive value of tumor-inﬁltrating lymphocytes in a phase III randomized
adjuvant breast cancer trial in node-positive breast cancer comparing the addi-
tion of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-
98. J. Clin. Oncol. 31, 860–867 (2013).
18. Ali, H. R., Provenzano, E., Dawson, S.-J., Blows, F. M., Liu, B. & Shah, M. et al.
Association between CD8+ T-cell inﬁltration and breast cancer survival in 12,439
patients. Ann. Oncol. J. Eur. Soc. Med. Oncol. 25, 1536–43 (2014).
19. Udler, M., Maia, A.-T., Cebrian, A., Brown, C., Greenberg, D. & Shah, M. et al.
Common germline genetic variation in antioxidant defense genes and survival
after diagnosis of breast cancer. J. Clin. Oncol. 25, 3015–23 (2007).
20. Einarsdóttir, K., Darabi, H., Li, Y., Low, Y. L., Li, Y. Q. & Bonnard, C. et al. ESR1 and
EGFgenetic variation in relation to breast cancer risk and survival. Breast Cancer
Res 10, R15 (2008).
21. Fasching, P. A., Loehberg, C. R., Strissel, P. L., Lux, M. P., Bani, M. R. & Schrauder, M.
et al. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/
neu status, and prognosis in breast cancer patients. Breast Cancer Res. Treat. 112,
89–98 (2008).
22. Schmidt, M. K., Tommiska, J., Broeks, A., van Leeuwen, F. E., Van’t Veer, L. J. &
Pharoah, P. D. P. et al. Combined effects of single nucleotide polymorphisms
TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer
patients. Breast Cancer Res. 11, R89 (2009).
23. Varadi, V., Brendle, A., Brandt, A., Johansson, R., Enquist, K. & Henriksson, R. et al.
Polymorphisms in telomere-associated genes, breast cancer susceptibility and
prognosis. Eur. J. Cancer 45, 3008–3016 (2009).
24. Lin, W.-Y., Camp, N. J., Cannon-Albright, L. A., Allen-Brady, K., Balasubramanian, S.
& Reed, M. W. R. et al. A role for XRCC2 gene polymorphisms in breast cancer risk
and survival. J. Med. Genet. 48, 477–484 (2011).
Genome-wide association study of germline variants and breast. . .
M Escala-Garcia et al.
653
25. Fasching, P. A., Pharoah, P. D. P., Cox, A., Nevanlinna, H., Bojesen, S. E. & Karn, T.
et al. The role of genetic breast cancer susceptibility variants as prognostic fac-
tors. Hum. Mol. Genet. 21, 3926–39 (2012).
26. Barrdahl, M., Canzian, F., Lindström, S., Shui, I., Black, A. & Hoover, R. N. et al.
Association of breast cancer risk loci with breast cancer survival. Int J. Cancer 137,
2837–2845 (2015).
27. Jamshidi, M., Fagerholm, R., Khan, S., Aittomäki, K., Czene, K. & Darabi, H. et al.
SNP–SNP interaction analysis of NF-κB signaling pathway on breast cancer sur-
vival. Oncotarget 6, 37979–94 (2015).
28. Weischer, M., Nordestgaard, B. G., Pharoah, P., Bolla, M. K., Nevanlinna, H. & Van’t
Veer, L. J. et al. CHEK2*1100delC heterozygosity in women with breast cancer
associated with early death, breast cancer-speciﬁc death, and increased risk of a
second breast cancer. J. Clin. Oncol. 30, 4308–16 (2012).
29. Pirie, A., Guo, Q., Kraft, P., Canisius, S., Eccles, D. M. & Rahman, N. et al. Common
germline polymorphisms associated with breast cancer-speciﬁc survival. Breast
Cancer Res. 17, 58 (2015).
30. Ambrosone, C. B., Sweeney, C., Coles, B. F., Thompson, P. A., McClure, G. Y. &
Korourian, S. et al. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1)
and survival after treatment for breast cancer. Cancer Res. 61, 7130–5 (2001).
31. Goode, E. L., Dunning, A. M., Kuschel, B., Healey, C. S., Day, N. E. & Ponder, B. A. J.
et al. Effect of germ-line genetic variation on breast cancer survival in a
population-based study. Cancer Res. 62, 3052–7 (2002).
32. Ambrosone, C. B., Ahn, J., Singh, K. K., Rezaishiraz, H., Furberg, H. & Sweeney, C.
et al. Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and
survival after treatment for breast cancer. Cancer Res. 65, 1105–11 (2005).
33. Boersma, B. J., Howe, T. M., Goodman, J. E., Yfantis, H. G., Lee, D. H. & Chanock, S. J.
et al. Association of breast cancer outcome with status of p53 and MDM2
SNP309. J. Natl. Cancer Inst. 98, 911–9 (2006).
34. Thussbas, C., Nahrig, J., Streit, S., Bange, J., Kriner, M. & Kates, R. et al. FGFR4
Arg388 allele is associated with resistance to adjuvant therapy in primary breast
cancer. J. Clin. Oncol. 24, 3747–3755 (2006).
35. Decock, J., Long, J.-R., Laxton, R. C., Shu, X.-O., Hodgkinson, C. & Hendrickx, W.
et al. Association of matrix metalloproteinase-8 gene variation with breast cancer
prognosis. Cancer Res. 67, 10214–10221 (2007).
36. Hughes, S., Agbaje, O., Bowen, R. L., Holliday, D. L., Shaw, J. A. & Duffy, S. et al.
Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes pre-
dict breast cancer progression. Clin. Cancer Res. 13, 6673–80 (2007).
37. Azzato, E. M., Pharoah, P. D. P., Harrington, P., Easton, D. F., Greenberg, D. &
Caporaso, N. E. et al. A genome-wide association study of prognosis in breast
cancer. Cancer Epidemiol. Biomark. Prev. 19, 1140–1143 (2010).
38. Azzato, E. M., Tyrer, J., Fasching, P. A., Beckmann, M. W., Ekici, A. B. & Schulz-
Wendtland, R. et al. Association between a germline OCA2 polymorphism at
chromosome 15q13.1 and estrogen receptor-negative breast cancer survival. J.
Natl. Cancer Inst. 102, 650–62 (2010).
39. Kiyotani, K., Mushiroda, T., Tsunoda, T., Morizono, T., Hosono, N. & Kubo, M. et al. A
genome-wide association study identiﬁes locus at 10q22 associated with clinical
outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese.
Hum. Mol. Genet. 21, 1665–72 (2012).
40. Shu, X. O., Long, J., Lu, W., Li, C., Chen, W. Y. & Delahanty, R. et al. Novel genetic
markers of breast cancer survival identiﬁed by a genome-wide association study.
Cancer Res. 72, 1182–9 (2012).
41. Raﬁq, S., Tapper, W., Collins, A., Khan, S., Politopoulos, I. & Gerty, S. et al. Identi-
ﬁcation of inherited genetic variations inﬂuencing prognosis in early-onset breast
cancer. Cancer Res. 73, 1883–91 (2013).
42. Raﬁq, S., Khan, S., Tapper, W., Collins, A., Upstill-Goddard, R. & Gerty, S. et al. A
genome wide meta-analysis study for identiﬁcation of common variation asso-
ciated with breast cancer prognosis. PLoS One 9, e101488 (2014).
43. Michailidou, K., Beesley, J., Lindstrom, S., Canisius, S., Dennis, J. & Lush, M. J. et al.
Genome-wide association analysis of more than 120,000 individuals identiﬁes 15
new susceptibility loci for breast cancer. Nat. Genet. 47, 373–380 (2015).
44. Guo, Q., Schmidt, M. K., Kraft, P., Canisius, S., Chen, C. & Khan, S. et al. Identiﬁ-
cation of novel genetic markers of breast cancer survival. J. Natl Cancer Inst. 107,
djv081–djv081 (2015).
45. Amos, C. I., Dennis, J., Wang, Z., Byun, J., Schumacher, F. R. & Gayther, S. A. et al.
The OncoArray Consortium: a network for understanding the genetic architecture
of common cancers. Cancer Epidemiol. Biomark. Prev. 26, 126–135 (2017).
46. Michailidou, K., Lindström, S., Dennis, J., Beesley, J., Hui, S. & Kar, S. et al. Association
analysis identiﬁes 65 new breast cancer risk loci. Nature 551, 92–94 (2017).
47. dbGaP (SUCCESS). https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?
study_id=phs000547. v1.p1.
48. van den Broek, A. J., Van’t Veer, L. J., Hooning, M. J., Cornelissen, S., Broeks, A. &
Rutgers, E. J. et al. Impact of age at primary breast cancer on contralateral breast
cancer risk in BRCA1/2 mutation carriers. J. Clin. Oncol. 34, 409–18 (2016).
49. Sankararaman, S., Sridhar, S., Kimmel, G. & Halperin, E. Estimating local ancestry in
admixed populations. Am. J. Hum. Genet. 82, 290–303 (2008).
50. Li, Y., Willer, C., Sanna, S. & Abecasis, G. Genotype imputation. Annu Rev. Genomics
Hum. Genet. 10, 387–406 (2009).
51. Delaneau, O., Marchini, J. & Zagury, J.-F. A linear complexity phasing method for
thousands of genomes. Nat. Methods 9, 179–81 (2011).
52. Howie, B., Marchini, J. & Stephens, M. Genotype imputation with thousands of
genomes. G3 (Bethesda) 1, 457–70 (2011).
53. Azzato, E. M., Greenberg, D., Shah, M., Blows, F., Driver, K. E. & Caporaso, N. E. et al.
Prevalent cases in observational studies of cancer survival: do they bias hazard
ratio estimates? Br. J. Cancer 100, 1806–1811 (2009).
54. Cox DR, Hinkley D V. Theoretical Statistics. Springer US: Boston, MA, 1974 https://
doi.org/10.1007/978-1-4899-2887-0.
55. Aulchenko, Y. S., Ripke, S., Isaacs, A. & van Duijn, C. M. GenABEL: an R library for
genome-wide association analysis. Bioinformatics 23, 1294–1296 (2007).
56. Ma, C., Blackwell, T., Boehnke, M. & Scott, L. J., GoT2D investigators. Recom-
mended joint and meta-analysis strategies for case–control association testing of
single low-count variants. Genet. Epidemiol. 37, 539–50 (2013).
57. Wakeﬁeld, J. A Bayesian measure of the probability of false discovery in genetic
epidemiology studies. Am. J. Hum. Genet. 81, 208–227 (2007).
58. Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W., Ernst, J., Bilenky,
M. & Yen, A. et al. Integrative analysis of 111 reference human epigenomes.
Nature 518, 317–329 (2015).
59. Dunham, I., Kundaje, A., Aldred, S. F., Collins, P. J., Davis, C. A. & Doyle, F. et al. An
integrated encyclopedia of DNA elements in the human genome. Nature 489,
57–74 (2012).
60. Aguet, F., Brown, A. A., Castel, S. E., Davis, J. R., He, Y. & Jo, B. et al. Genetic effects
on gene expression across human tissues. Nature 550, 204–213 (2017).
61. Edwards, S. L., Beesley, J., French, J. D. & Dunning, A. M. Beyond GWASs: illuminating
the dark road from association to function. Am. J. Hum. Genet. 93, 779–797 (2013).
62. Machiela, M. J. & Chanock, S. J. LDlink: a web-based application for exploring
population-speciﬁc haplotype structure and linking correlated alleles of possible
functional variants. Bioinformatics 31, 3555–7 (2015).
63. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping
and annotation of genetic associations with FUMA. Nat. Commun. 8, 1826 (2017).
64. Novak, P., Jensen, T., Oshiro, M. M., Wozniak, R. J., Nouzova, M. & Watts, G. S. et al.
Epigenetic inactivation of the HOXA gene cluster in breast cancer. Cancer Res. 66,
10664–10670 (2006).
65. Xia, B., Shan, M., Wang, J., Zhong, Z., Geng, J. & He, X. et al. Homeobox A11
hypermethylation indicates unfavorable prognosis in breast cancer. Oncotarget 8,
9794–9805 (2017).
66. Yang, Y., Qian, J., Xiang, Y., Chen, Y. & Qu, J. The prognostic value of long noncoding
RNA HOTTIP on clinical outcomes in breast cancer. Oncotarget 8, 6833–6844 (2017).
67. Choi, H. & Lee, S. K. TAX1BP1 downregulation by EBV-miR-BART15-3p enhances
chemosensitivity of gastric cancer cells to 5-FU. Arch. Virol. 162, 369–377 (2017).
68. Nakayama, Y., Nakamura, N., Oki, S., Wakabayashi, M., Ishihama, Y. & Miyake, A.
et al. A putative polypeptide N-acetylgalactosaminyltransferase/Williams–Beuren
syndrome chromosome region 17 (WBSCR17) regulates lamellipodium formation
and macropinocytosis. J. Biol. Chem. 287, 32222–32235 (2012).
69. Gao, Z., Lee, P., Stafford, J. M., von Schimmelmann, M., Schaefer, A. & Reinberg, D.
An AUTS2–Polycomb complex activates gene expression in the CNS. Nature 516,
349–354 (2014).
70. Han, Y., Ru, G.-Q., Mou, X., Wang, H., Ma, Y. & He, X.-L. et al. AUTS2 is a potential
therapeutic target for pancreatic cancer patients with liver metastases. Med.
Hypotheses 85, 203–206 (2015).
71. Kadalayil, L., Khan, S., Nevanlinna, H., Fasching, P. A., Couch, F. J. & Hopper, J. L.
et al. Germline variation in ADAMTSL1 is associated with prognosis following
breast cancer treatment in young women. Nat. Commun. 8, 1632 (2017).
72. Kao, P. Y. P., Leung, K. H., Chan, L. W. C., Yip, S. P. & Yap, M. K. H. Pathway analysis
of complex diseases for GWAS, extending to consider rare variants, multi-omics
and interactions. Biochim. Biophys. Acta 1861, 335–353 (2017).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2019
Genome-wide association study of germline variants and breast. . .
M Escala-Garcia et al.
654
AFFILIATIONS
Maria Escala-Garcia1, Qi Guo2, Thilo Dörk3, Sander Canisius1,4, Renske Keeman1, Joe Dennis5, Jonathan Beesley6, Julie Lecarpentier5,
Manjeet K. Bolla5, Qin Wang5, Jean Abraham7,8,9, Irene L. Andrulis10,11, Hoda Anton-Culver12, Volker Arndt13, Paul L. Auer14,15,
Matthias W. Beckmann16, Sabine Behrens17, Javier Benitez18,19, Marina Bermisheva20, Leslie Bernstein21, Carl Blomqvist22,23,
Bram Boeckx24,25, Stig E. Bojesen26,27,28, Bernardo Bonanni29, Anne-Lise Børresen-Dale30,31,32,33,34,35,36,37,38,39, Hiltrud Brauch40,41,42,
Hermann Brenner13,42,43, Adam Brentnall44, Louise Brinton45, Per Broberg46, Ian W. Brock47, Sara Y. Brucker48, Barbara Burwinkel49,50,
Carlos Caldas8,9,51, Trinidad Caldés52, Daniele Campa17,53, Federico Canzian50, Angel Carracedo54,55,56, Brian D. Carter57,
Jose E. Castelao58, Jenny Chang-Claude17,59, Stephen J. Chanock45, Georgia Chenevix-Trench6, Ting-Yuan David Cheng60,
Suet-Feung Chin61, Christine L. Clarke62, NBCS Collaborators, Emilie Cordina-Duverger63, Fergus J. Couch64, David G. Cox65,66,
Angela Cox47, Simon S. Cross67, Kamila Czene68, Mary B. Daly69, Peter Devilee70,71, Janet A. Dunn72, Alison M. Dunning7,
Lorraine Durcan73,74, Miriam Dwek75, Helena M. Earl9,76, Arif B. Ekici77, A. Heather Eliassen78,79, Carolina Ellberg46, Christoph Engel80,81,
Mikael Eriksson68, D. Gareth Evans82,83, Jonine Figueroa45,84,85, Dieter Flesch-Janys86,87, Henrik Flyger88, Marike Gabrielson68,
Manuela Gago-Dominguez54,89, Eva Galle24,25, Susan M. Gapstur57, Montserrat García-Closas45,90, José A. García-Sáenz52,
Mia M. Gaudet57, Angela George91,92, Vassilios Georgoulias93, Graham G. Giles94,95,96, Gord Glendon10, David E. Goldgar97,
Anna González-Neira18, Grethe I. Grenaker Alnæs30, Mervi Grip98, Pascal Guénel63, Lothar Haeberle99, Eric Hahnen100,101,
Christopher A. Haiman102, Niclas Håkansson103, Per Hall68,104, Ute Hamann105, Susan Hankinson106, Elaine F. Harkness107,108,109,
Patricia A. Harrington7, Steven N. Hart110, Jaana M. Hartikainen111,112,113, Alexander Hein16, Peter Hillemanns3, Louise Hiller72,
Bernd Holleczek114, Antoinette Hollestelle115, Maartje J. Hooning115, Robert N. Hoover45, John L. Hopper95, Anthony Howell116,
Guanmengqian Huang105, Keith Humphreys68, David J. Hunter79,117,118, Wolfgang Janni119, Esther M. John120,121,122, Michael E. Jones90,
Arja Jukkola-Vuorinen123, Audrey Jung17, Rudolf Kaaks17, Maria Kabisch105, Katarzyna Kaczmarek124, Michael J. Kerin125, Soﬁa Khan126,
Elza Khusnutdinova20,127, Johanna I. Kiiski126, Cari M. Kitahara128, Julia A. Knight129,130, Yon-Dschun Ko131, Linetta B. Koppert132,
Veli-Matti Kosma111,112,113, Peter Kraft79,117, Vessela N. Kristensen30,31,32,33,34,35,36,37,38,39, Ute Krüger46, Tabea Kühl59,
Diether Lambrechts24,25, Loic Le Marchand133, Eunjung Lee102, Flavio Lejbkowicz134, Lian Li135, Annika Lindblom136,
Sara Lindström137,138, Martha Linet128, Jolanta Lissowska139, Wing-Yee Lo40,41, Sibylle Loibl140, Jan Lubiński124, Michael P. Lux99,
Robert J. MacInnis94,95, Melanie Maierthaler50, Tom Maishman73,74, Enes Makalic95, Arto Mannermaa111,112,113, Mehdi Manoochehri105,
Siranoush Manoukian141, Sara Margolin142, Maria Elena Martinez89,143, Dimitrios Mavroudis93, Catriona McLean144, Alfons Meindl145,
Pooja Middha17,146, Nicola Miller125, Roger L. Milne94,95, Fernando Moreno52, Anna Marie Mulligan147,148, Claire Mulot149,
Rami Nassir150, Susan L. Neuhausen21, William T. Newman82,83, Sune F. Nielsen26,27, Børge G. Nordestgaard26,27,28, Aaron Norman110,
Håkan Olsson46, Nick Orr151, V. Shane Pankratz152, Tjoung-Won Park-Simon3, Jose I. A. Perez153, Clara Pérez-Barrios154,
Paolo Peterlongo155, Christos Petridis156, Mila Pinchev134, Karoliona Prajzendanc124, Ross Prentice14, Nadege Presneau75,
Darya Prokoﬁeva127, Katri Pylkäs157,158, Brigitte Rack145, Paolo Radice159, Dhanya Ramachandran3, Gadi Rennert134, Hedy S. Rennert134,
Valerie Rhenius7, Atocha Romero154, Rebecca Roylance160, Emmanouil Saloustros161, Elinor J. Sawyer156, Daniel F. Schmidt95,
Rita K. Schmutzler100,101, Andreas Schneeweiss49,162, Minouk J. Schoemaker91, Fredrick Schumacher163, Lukas Schwentner119,
Rodney J. Scott164,165,166,167, Christopher Scott110, Caroline Seynaeve115, Mitul Shah7, Jacques Simard168, Ann Smeets169,
Christof Sohn162, Melissa C. Southey170,171, Anthony J. Swerdlow91,172, Aline Talhouk173,174,175, Rulla M. Tamimi78,79,117,
William J. Tapper176, Manuel R. Teixeira177,178, Maria Tengström111,179,180, Mary Beth Terry181, Kathrin Thöne59, Rob A. E. M. Tollenaar182,
Ian Tomlinson183,184, Diana Torres105,185, Thérèse Truong63, Constance Turman79, Clare Turnbull91, Hans-Ulrich Ulmer186,
Michael Untch187, Celine Vachon110, Christi J. van Asperen188, Ans M. W. van den Ouweland189, Elke M. van Veen82,83, Camilla Wendt190,
Alice S. Whittemore121,122, Walter Willett79,191,192, Robert Winqvist157,158, Alicja Wolk193, Xiaohong R. Yang45, Yan Zhang13,42,
Douglas F. Easton5,7, Peter A. Fasching16,194, Heli Nevanlinna126, Diana M. Eccles74, Paul D. P. Pharoah5,7 and Marjanka K. Schmidt1,195
1The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Division of Molecular Pathology, Amsterdam, The Netherlands; 2University
of Cambridge, Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, Cambridge, UK; 3Hannover Medical School,
Gynaecology Research Unit, Hannover, Germany; 4The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Division of Molecular
Carcinogenesis, Amsterdam, The Netherlands; 5University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health
and Primary Care, Cambridge, UK; 6QIMR Berghofer Medical Research Institute, Department of Genetics and Computational Biology, Brisbane,
Queensland, Australia; 7University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, UK; 8Cambridge
Experimental Cancer Medicine Centre, Cambridge, UK; 9University of Cambridge NHS Foundation Hospitals, Cambridge Breast Unit and NIHR
Cambridge Biomedical Research Centre, Cambridge, UK; 10Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Fred A. Litwin Center
for Cancer Genetics, Toronto, ON, Canada; 11University of Toronto, Department of Molecular Genetics, Toronto, ON, Canada; 12University of
California Irvine, Department of Epidemiology, Genetic Epidemiology Research Institute, Irvine, CA, USA; 13German Cancer Research Center (DKFZ),
Division of Clinical Epidemiology and Aging Research, Heidelberg, Germany; 14Fred Hutchinson Cancer Research Center, Cancer Prevention
Program, Seattle, WA, USA; 15University of Wisconsin-Milwaukee, Zilber School of Public Health, Milwaukee, WI, USA; 16University Hospital
Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN,
Erlangen, Germany; 17German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany; 18Spanish National Cancer
Research Centre (CNIO), Human Cancer Genetics Programme, Madrid, Spain; 19Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain;
20Ufa Scientiﬁc Center of Russian Academy of Sciences, Institute of Biochemistry and Genetics, Ufa, Russia; 21Beckman Research Institute of City of
Hope, Department of Population Sciences, Duarte, CA, USA; 22University of Helsinki, Department of Oncology, Helsinki University Hospital, Helsinki,
Finland; 23Örebro University Hospital, Department of Oncology, Örebro, Sweden; 24VIB, VIB Center for Cancer Biology, Leuven, Belgium;
25University of Leuven, Laboratory for Translational Genetics, Department of Human Genetics, Leuven, Belgium; 26Copenhagen University
Hospital, Copenhagen General Population Study, Herlevand Gentofte Hospital, Herlev, Denmark; 27Copenhagen University Hospital, Department
of Clinical Biochemistry, Herlev and Gentofte Hospital, Herlev, Denmark; 28University of Copenhagen, Faculty of Health and Medical Sciences,
Copenhagen, Denmark; 29Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS Milan, Milan 20141, Italy; 30Oslo
Genome-wide association study of germline variants and breast. . .
M Escala-Garcia et al.
655
University Hospital-Radiumhospitalet, Department of Cancer Genetics, Institute for Cancer Research, Oslo, Norway; 31University of Oslo, Institute of
Clinical Medicine, Faculty of Medicine, Oslo, Norway; 32Department of Research, Vestre Viken Hospital, Drammen, Norway; Section for Breast- and
Endocrine Surgery, Department of Cancer, Division of Surgery, Cancer and Transplantation Medicine, Oslo University Hospital-Ullevål, Oslo,
Norway; 33Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway; 34Department of Pathology at Akershus
University hospital, Lørenskog, Norway; 35Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway;
36Department of Oncology, Division of Surgery and Cancer and Transplantation Medicine, Oslo University Hospital-Radiumhospitalet, Oslo,
Norway; 37National Advisory Unit on Late Effects after Cancer Treatment, Department of Oncology, Oslo University Hospital, Oslo, Norway;
38Department of Oncology, Akershus University Hospital, Lørenskog, Norway; 39Breast Cancer Research Consortium, Oslo University Hospital, Oslo,
Norway; 40Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany; 41University of Tübingen, Tübingen, Germany;
42German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany; 43German Cancer Research Center (DKFZ)
and National Center for Tumor Diseases (NCT), Division of Preventive Oncology, Heidelberg, Germany; 44Queen Mary University of London, Centre
for Cancer Prevention, Wolfson Institute of Preventive Medicine, London, UK; 45National Cancer Institute, Division of Cancer Epidemiology and
Genetics, Bethesda, MD, USA; 46Lund University, Department of Cancer Epidemiology, Clinical Sciences, Lund, Sweden; 47University of Shefﬁeld,
Shefﬁeld Institute for Nucleic Acids (SInFoNiA), Department of Oncology and Metabolism, Shefﬁeld, UK; 48University of Tübingen, Department of
Gynecology and Obstetrics, Tübingen, Germany; 49University of Heidelberg, Department of Obstetrics and Gynecology, Heidelberg, Germany;
50German Cancer Research Center (DKFZ), Molecular Epidemiology Group, C080 Heidelberg, Germany; 51The Institute of Cancer Research, Section
of Cancer Genetics, London, UK; 52Instituto de Investigación Sanitaria San Carlos (IdISSC), Centro Investigación Biomédica en Red de Cáncer
(CIBERONC), Medical Oncology Department, Hospital Cl’nico San Carlos, Madrid, Spain; 53University of Pisa, Department of Biology, Pisa, Italy;
54Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Genomic Medicine Group, Galician Foundation of Genomic Medicine,
SERGAS, Santiago de Compostela, Spain; 55Universidad de Santiago de Compostela, Centro de Investigación en Red de Enfermedades Raras
(CIBERER), Santiago De Compostela, Spain; 56King Abdulaziz University, Center of Excellence in Genomic Medicine, Jeddah, Kingdom of Saudi
Arabia; 57American Cancer Society, Epidemiology Research Program, Atlanta, GA, USA; 58Instituto de Investigación Sanitaria Galicia Sur (IISGS),
Xerencia de Xestion Integrada de Vigo-SERGAS, Oncology and Genetics Unit, Vigo, Spain; 59University Medical Center Hamburg-Eppendorf, Cancer
Epidemiology Group, University Cancer Center Hamburg (UCCH), Hamburg, Germany; 60Roswell Park Cancer Institute, Division of Cancer
Prevention and Control, Buffalo, NY, USA; 61University of Cambridge, Cancer Research UK Cambridge Institute, Cambridge, UK; 62University of
Sydney, Westmead Institute for Medical Research, Sydney, NSW, Australia; 63INSERM, University Paris-Sud, University Paris-Saclay, Cancer &
Environment Group, Center for Research in Epidemiology and Population Health (CESP), Villejuif, France; 64Mayo Clinic, Department of Laboratory
Medicine and Pathology, Rochester, MN, USA; 65Imperial College London, Department of Epidemiology and Biostatistics, School of Public Health,
London, UK; 66Cancer Research Center of Lyon, INSERM U1052 Lyon, France; 67University of Shefﬁeld, Academic Unit of Pathology, Department of
Neuroscience, Shefﬁeld, UK; 68Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden; 69Fox Chase
Cancer Center, Department of Clinical Genetics, Philadelphia, PA, USA; 70Leiden University Medical Center, Department of Pathology, Leiden, The
Netherlands; 71Leiden University Medical Center, Department of Human Genetics, Leiden, The Netherlands; 72University of Warwick, Warwick
Clinical Trials Unit, Coventry, UK; 73University of Southampton, Southampton Clinical Trials Unit, Faculty of Medicine, Southampton, UK;
74University of Southampton, Cancer Sciences Academic Unit, Faculty of Medicine, Southampton, UK; 75University of Westminster, Department of
Biomedical Sciences, Faculty of Science and Technology, London, UK; 76University of Cambridge, Department of Oncology, Cambridge, UK;
77Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Institute of Human Genetics, University
Hospital Erlangen, Erlangen, Germany; 78Harvard Medical School, Channing Division of Network Medicine, Department of Medicine, Brigham and
Women’s Hospital, Boston, MA, USA; 79Harvard T.H. Chan School of Public Health, Department of Epidemiology, Boston, MA, USA; 80University of
Leipzig, Institute for Medical Informatics, Statistics and Epidemiology, Leipzig, Germany; 81University of Leipzig, LIFE - Leipzig Research Centre for
Civilization Diseases, Leipzig, Germany; 82University of Manchester, Manchester Academic Health Science Centre, Division of Evolution and
Genomic Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester, UK; 83St Marys Hospital, Central
Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester Centre for Genomic Medicine,
Manchester, UK; 84The University of Edinburgh Medical School, Usher Institute of Population Health Sciences and Informatics, Edinburgh, UK;
85Cancer Research UK Edinburgh Centre, Edinburgh, UK; 86University Medical Centre Hamburg-Eppendorf, Institute for Medical Biometrics and
Epidemiology, Hamburg, Germany; 87University Medical Centre Hamburg-Eppendorf, Department of Cancer Epidemiology, Clinical Cancer
Registry, Hamburg, Germany; 88Copenhagen University Hospital, Department of Breast Surgery, Herlev and Gentofte Hospital, Herlev, Denmark;
89University of California San Diego, Moores Cancer Center, La Jolla, CA, USA; 90Institute of Cancer Research, Division of Genetics and
Epidemiology, London, UK; 91The Institute of Cancer Research, Division of Genetics and Epidemiology, London, UK; 92The Royal Marsden NHS
Foundation Trust, Cancer Genetics Unit, London, UK; 93University Hospital of Heraklion, Department of Medical Oncology, Heraklion, Greece;
94Cancer Council Victoria, Cancer Epidemiology & Intelligence Division, Melbourne, VIC, Australia; 95The University of Melbourne, Melbourne
School of Population and Global Health, Centre for Epidemiology and Biostatistics, Melbourne, VIC, Australia; 96Monash University, Department of
Epidemiology and Preventive Medicine, Melbourne, VIC, Australia; 97Huntsman Cancer Institute, University of Utah School of Medicine,
Department of Dermatology, Salt Lake City, UT, USA; 98University of Oulu, Department of Surgery, Oulu University Hospital, Oulu, Finland;
99Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Centre Erlangen-EMN, Department of Gynaecology and Obstetrics,
University Hospital Erlangen, Erlangen, Germany; 100University Hospital of Cologne, Centre for Hereditary Breast and Ovarian Cancer, Cologne,
Germany; 101University of Cologne, Centre for Molecular Medicine Cologne (CMMC), Cologne, Germany; 102University of Southern California,
Department of Preventive Medicine, Keck School of Medicine, Los Angeles, CA, USA; 103Karolinska Institutet, Institute of Environmental Medicine,
Stockholm, Sweden; 104South General Hospital, Department of Oncology, Stockholm, Sweden; 105German Cancer Research Centre (DKFZ),
Molecular Genetics of Breast Cancer, Heidelberg, Germany; 106University of Massachusetts, Amherst, Department of Biostatistics & Epidemiology,
Amherst, MA, USA; 107University of Manchester, Manchester Academic Health Science Centre, Division of Informatics, Imaging and Data Sciences,
Faculty of Biology, Medicine and Health, Manchester, UK; 108Wythenshawe Hospital, Manchester University NHS Foundation Trust, Nightingale
Breast Screening Centre, Manchester, UK; 109Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, NIHR
Manchester Biomedical Research Unit, Manchester, UK; 110Mayo Clinic, Department of Health Sciences Research, Rochester, MN, USA; 111University
of Eastern Finland, Translational Cancer Research Area, Kuopio, Finland; 112University of Eastern Finland, Institute of Clinical Medicine, Pathology
and Forensic Medicine, Kuopio, Finland; 113Kuopio University Hospital, Imaging Centre, Department of Clinical Pathology, Kuopio, Finland;
114Saarland Cancer Registry, Saarbruecken, Germany; 115Erasmus MC Cancer Institute, Department of Medical Oncology, Family Cancer Clinic,
Rotterdam, The Netherlands; 116University of Manchester, Institute of Cancer studies, Manchester, UK; 117Harvard T.H. Chan School of Public
Health, Program in Genetic Epidemiology and Statistical Genetics, Boston, MA, USA; 118University of Oxford, Nufﬁeld Department of Population
Genome-wide association study of germline variants and breast. . .
M Escala-Garcia et al.
656
Health, Oxford, UK; 119Cancer Research UK Edinburgh Centre, Edinburgh, UK; 120Cancer Prevention Institute of California, Department of
Epidemiology, Fremont, CA, USA; 121Stanford University School of Medicine, Department of Health Research and Policy - Epidemiology, Stanford,
CA, USA; 122Stanford University School of Medicine, Department of Biomedical Data Science, Stanford, CA, USA; 123Tampere University Hospital,
Department of Oncology, Tampere, Finland; 124Pomeranian Medical University, Department of Genetics and Pathology, Szczecin, Poland;
125National University of Ireland, Surgery, School of Medicine, Galway, Ireland; 126University of Helsinki, Department of Obstetrics and
Gynaecology, Helsinki University Hospital, Helsinki, Finland; 127Bashkir State University, Department of Genetics and Fundamental Medicine, Ufa,
Russia; 128National Cancer Institute, Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA;
129Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Prosserman Centre for Population Health Research, Toronto, ON, Canada;
130University of Toronto, Division of Epidemiology, Dalla Lana School of Public Health, Toronto, ON, Canada; 131Johanniter Krankenhaus,
Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Bonn, Germany; 132Erasmus MC Cancer Institute, Department of Surgical
Oncology, Family Cancer Clinic, Rotterdam, The Netherlands; 133University of Hawaii Cancer Center, Epidemiology Program, Honolulu, HI, USA;
134Carmel Medical Center and Technion Faculty of Medicine, Clalit National Cancer Control Center, Haifa, Israel; 135Tianjin Medical University
Cancer Institute and Hospital, Department of Epidemiology, Tianjin, China; 136Karolinska Institutet, Department of Molecular Medicine and
Surgery, Stockholm, Sweden; 137University of Washington School of Public Health, Department of Epidemiology, Seattle, WA, USA; 138Fred
Hutchinson Cancer Research Center, Public Health Sciences Division, Seattle, WA, USA; 139M. Sklodowska-Curie Cancer Centre, Oncology Institute,
Department of Cancer Epidemiology and Prevention, Warsaw, Poland; 140GmbH, German Breast Group, Neu Isenburg, Germany; 141Fondazione
IRCCS (Istituto Di Ricovero e Cura a Carattere Scientiﬁco) Istituto Nazionale dei Tumori (INT), Unit of Medical Genetics, Department of Medical
Oncology and Haematology, Milan, Italy; 142Karolinska Institutet, Department of Clinical Science and Education, Sšdersjukhuset, Stockholm,
Sweden; 143University of California San Diego, Department of Family Medicine and Public Health, La Jolla, CA, USA; 144The Alfred Hospital,
Anatomical Pathology, Melbourne, VIC, Australia; 145Ludwig Maximilian University of Munich, Department of Gynaecology and Obstetrics, Munich,
Germany; 146University of Heidelberg, Faculty of Medicine, Heidelberg, Germany; 147University of Toronto, Department of Laboratory Medicine
and Pathobiology, Toronto, ON, Canada; 148University Health Network, Laboratory Medicine Program, Toronto, ON, Canada; 149INSERM UMR-
S1147, Université Paris Sorbonne Cité, Paris, France; 150University of California Davis, Department of Biochemistry and Molecular Medicine, Davis,
CA, USA; 151Queen’s University Belfast, Centre for Cancer Research and Cell Biology, Belfast, Ireland, UK; 152University of New Mexico, University of
New Mexico Health Sciences Center, Albuquerque, NM, USA; 153Hospital Monte Naranco, Servicio de Cirug’a General y Especialidades, Oviedo,
Spain; 154Hospital Universitario Puerta de Hierro, Medical Oncology Department, Madrid, Spain; 155The FIRC (Italian Foundation for Cancer
Research) Institute of Molecular Oncology, IFOM, Milan, Italy; 156King’s College London, Research Oncology, Guy’s Hospital, London, UK;
157University of Oulu, Laboratory of Cancer Genetics and Tumour Biology, Cancer and Translational Medicine Research Unit, Biocentre Oulu, Oulu,
Finland; 158Northern Finland Laboratory Centre Oulu, Laboratory of Cancer Genetics and Tumour Biology, Oulu, Finland; 159Fondazione IRCCS
(Istituto Di Ricovero e Cura a Carattere Scientiﬁco) Istituto Nazionale dei Tumori (INT), Unit of Molecular Bases of Genetic Risk and Genetic Testing,
Department of Research, Milan, Italy; 160UCLH Foundation Trust, Department of Oncology, London, UK; 161University Hospital of Larissa,
Department of Oncology, Larissa, Greece; 162University of Heidelberg, National Centre for Tumour Diseases, Heidelberg, Germany; 163Case Western
Reserve University, Department of Population and Quantitative Health Sciences, Cleveland, OH, USA; 164John Hunter Hospital, Division of
Molecular Medicine, Pathology North, Newcastle, NSW, Australia; 165University of Newcastle, Discipline of Medical Genetics, School of Biomedical
Sciences and Pharmacy, Faculty of Health, Callaghan, NSW, Australia; 166John Hunter Hospital, Hunter Medical Research Institute, Newcastle, NSW,
Australia; 167University of Newcastle, Centre for Information Based Medicine, Callaghan, Newcastle, NSW, Australia; 168Centre Hospitalier
Universitaire de Québec - Université Laval Research Centre, Genomics Centre, Québec City, QC, Canada; 169University Hospitals Leuven,
Department of Surgical Oncology, Leuven, Belgium; 170Monash University, Precision Medicine, School of Clinical Sciences at Monash Health,
Clayton, Victoria, Australia; 171The University of Melbourne, Department of Clinical Pathology, Melbourne, VIC, Australia; 172The Institute of Cancer
Research, Division of Breast Cancer Research, London, UK; 173BC Cancer Agency and University of British Columbia, British Columbia’s Ovarian
Cancer Research (OVCARE) Program, Vancouver General Hospital, Vancouver, BC, Canada; 174University of British Columbia, Department of
Pathology and Laboratory Medicine, Vancouver, BC, Canada; 175University of British Columbia, Department of Obstetrics and Gynaecology,
Vancouver, BC, Canada; 176University of Southampton, Faculty of Medicine, Southampton, UK; 177Portuguese Oncology Institute, Department of
Genetics, Porto, Portugal; 178University of Porto, Biomedical Sciences Institute (ICBAS), Porto, Portugal; 179Kuopio University Hospital, Cancer
Centre, Kuopio, Finland; 180University of Eastern Finland, Institute of Clinical Medicine, Oncology, Kuopio, Finland; 181Columbia University,
Department of Epidemiology, Mailman School of Public Health, New York, NY, USA; 182Leiden University Medical Centre, Department of Surgery,
Leiden, The Netherlands; 183University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, UK; 184University of Oxford,
Wellcome Trust Centre for Human Genetics and Oxford NIHR Biomedical Research Centre, Oxford, UK; 185Pontiﬁcia Universidad Javeriana, Institute
of Human Genetics, Bogota, Colombia; 186Frauenklinik der Stadtklinik Baden-Baden, Baden-Baden, Germany; 187Helios Clinics Berlin-Buch,
Department of Gynaecology and Obstetrics, Berlin, Germany; 188Leiden University Medical Centre, Department of Clinical Genetics, Leiden, The
Netherlands; 189Erasmus University Medical Centre, Department of Clinical Genetics, Rotterdam, The Netherlands; 190Karolinska Institutet,
Department of Clinical Science and Education, Södersjukhuset, Stockholm, Sweden; 191Harvard T.H. Chan School of Public Health, Department of
Nutrition, Boston, MA, USA; 192Brigham and Women’s Hospital and Harvard Medical School, Channing Division of Network Medicine, Boston, MA,
USA; 193Karolinska Institutet, Department of Environmental Medicine, Division of Nutritional Epidemiology, Stockholm, Sweden; 194University of
California at Los Angeles, David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, Los Angeles, CA, USA
and 195The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Division of Psychosocial Research and Epidemiology, Amsterdam,
The Netherlands
Genome-wide association study of germline variants and breast. . .
M Escala-Garcia et al.
657
